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ABSTRACT
A retrospective study was performed in children (aged one month – 16 years) receiving HFNC to determine the frequency,
efficacy and adverse effects of high flow nasal cannula (HFNC) therapy in the pediatric intensive care unit (PICU), from January
to December 2017.  Treatment failure was defined as clinical  deterioration on HFNC therapy such that mechanical  ventilation
(MV) was required. Clinical parameters before and after HFNC were assessed using repeated measures analysis of variance. A
total of 120 patients received HFNC therapy (21% of total admissions). Primary diagnosis were respiratory disease (50%),
central nervous system diseases (14.2%), sepsis (10.8%), and postoperative care (10%). Mean duration of HFNC was 27.5
±19.7 hours and mean PICU length of stay was 6 ± 6 days. Pneumothorax developed in four patients. MV was required in 28
patients, and subsequently, 15 deaths occurred in that group. HFNC is a frequently used, safe and effective therapy for children
requiring respiratory support in PICU.
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Respiratory illnesses are one of the leading causes for pediatric
intensive  care  unit  (PICU)  admission  (26.3%).1  Respiratory
support  in  PICU has evolved from predominantly  mechanical
ventilation (MV) to non-invasive ventilation. This has markedly
reduced complications related to invasive mechanical ventila-
tion.2,3 Heated, humidified, high-flow nasal cannula (HFNC) is a
relatively new method of respiratory support.4 HFNC washes out
the carbon dioxide-rich gas in a portion of the anatomical dead
space  and  potentially  provides  positive  airway  pressure.
Humidification saves energy spent warming and enables better
tolerance by decreasing the risk of nasal trauma.5 Previous clin-
ical studies using HFNC therapy have shown a reduction in intuba-
tion  rates  in  critically  ill  infants  in  PICU  with  a  better  safety
profile.3,4,6
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We describe use of HFNC in our PICU. This study will pave the
path for larger studies on use of HFNC in children with acute
respiratory distress.
Retrospective review of medical records of children (aged one
month – 16 years) admitted in PICU of the Aga Khan University
Hospital  and  received  HFNC,  was  done  from  January  to
December 2017 after ethical approval (2019-1036-2634). The
decision to start HFNC was based on patients’ clinical condition
[respiratory  distress  defined  as  increased  respiratory  rate,
increased work of breathing, oxygen saturation as per standard
pediatric advanced life support (PALS) guidelines],  hemody-
namic stability (age-appropriate normal heart rate, perfusion
and blood pressure as per PALS criteria), normal Glasgow coma
scale (GCS) and oxygen saturation (SaO2) and attending physi-
cian discretion. Patients with SaO2 <88% on pulse oximetry,
GCS  <12,  and  hemodynamic  instability  were  not  provided
HFNC. HFNC was provided at the maximum rate of 2 litres/kilo-
gramme body weight/minute, through Optiflow® system with
age appropriate nasal cannulas (Fisher and Paykel Healthcare).
HFNC was switched to O2 by nasal prongs, if patient was at <40%
FiO2 for more than 6 hours with stable vital signs and work of
breathing, and was labelled HFNC success.
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Table I: Comparison of variables between high flow nasal cannula success and failure.
 
 
High flow nasal cannula failure
(intubated)
n=28
High flow nasal cannula success
(non-intubated)
n=92
Independent  t-test /
Chi-square test
p-value (95% CI)
Heart rate Mean ± SD* Mean ± SD  
0 hours (before start of HFNC) 154 ± 21 145.6 ± 21 0.11
At 2 hours of HFNC 135 ± 13 125.38 ± 21 0.034
At end of HFNC 127.18 ± 26 115.11 ± 19 0.01
Respiratory rate    
0 hours (before start) 46.7 ± 13 49.30 ± 12 0.35
2 hours 39.6 ± 14 35.37 ± 8 0.066
End of HFNC 35.82 ± 18 28.67 ± 8 0.003
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*SD = standard deviation.
If  a  patient had SaO2  <88% on HFNC, FiO2  requirements
>70%,  respiratory  distress  or  hemodynamic  instability,
HFNC treatment was regarded as failure and MV was insti-
tuted.  Patients  were  also  observed  for  development  of
complication (pneumothorax) detected on chest X-ray.
Data  collection  included demographic,  clinical,  and  HFNC
details. Chi-square / T-test were applied to compare HFNC
success versus  failure.  A p-value of  <0.05 was taken as
significant.
A total of 120 patients met the inclusion criteria, making
21% of total PICU admissions. The primary diagnosis was
respiratory  system  diseases  (60,  50%),  central  nervous
system diseases (17, 14.2%), sepsis (13, 10.8%), postopera-
tive care (12, 10%) and miscellaneous (two patients with
acute kidney injury and severe diabetic ketoacidosis each
and one patient with severe malnutrition).
Mean HFNC duration was 27.5 ±19.7 hours, while mean PICU
length  of  stay  was  6  ±  6  days.  Twenty-eight  patients
(23.3%) failed HFNC and required MV. Complication (pneu-
mothorax) developed in four (3.3%) and all survived. Mean
heart rate and respiratory rate decreased significantly in all
patients after two hours of HFNC therapy (p < 0.05, Table I).
This  difference  was  more  pronounced  in  patients  in  whom
HFNC was successful  as compared to patients who failed
HFNC therapy (Table I). The SaO2 / FiO2 ratio was same in
both groups (p=0.59). Fifteen (12.5%) patients died, under-
lying cause was acute respiratory distress syndrome (ARDS)
in seven, acute heart failure in four, sepsis in two, and acute
leukemia with relapse in one.
HFNC is being increasingly used in children for a variety of
conditions.2 Recent studies have shown HFNC to be effective
in  infants  with  bronchiolitis,  requiring  less  escalation  of
therapy compared to standard therapy.6
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Escalation to MV (23%) in this study was higher than in
previous studies of 8-18%.3,6  Amongst patients who failed
HFNC, there were 15 deaths and failure of HFNC could be
due  to  the  severity  of  presenting  disease.  However,
mechanical ventilation was not warranted at the start of
treatment in any of the patients and so there was clinical
equipoise as to the use of HFNC at this stage of disease
evolution, allowing us to determine our own criteria for its
use.  This  study  did  not  consider  the  diagnosis-specific
failure  rate.
Pneumothorax was the main complication observed in this
study. Previous report show frequency of <1% of develop-
ment of pneumothorax with HFNC.3,6 Pneumothorax on HFNC
develops  with  severe  underlying  lung disease  or  due to
formation of  seal  around the nasal  cannula due to thick
secretions or inappropriate nasal cannula size.
Pneumothorax was small in all these patients with no hemo-
dynamic instability and spontaneous resolution in three, one
required chest drain insertion. It could be related to under-
lying disease process but further exploration into the cause
of pneumothorax was not possible because of type of study
design.
Heart  rate  and  respiratory  rate  improved  significantly
within two hours of start of HFNC therapy in all the patients,
and  this  difference  was  significant  in  patients  with  HFNC
success compared to those who failed the intervention. This
means that clinical status assessment after two hours of
starting HFNC therapy is important and can be a predictor
of  HFNC  therapy  success.  Further  studies  must  be
performed to explore this. SaO2 and FiO2 ratio (a marker of
severity of hypoxia and disease) were similar in the both
the groups.
The study has limitations of being a single centre, retrospec-
tive and small sample size. Further studies may identify reli-
able cardiorespiratory and diagnostic predictors of therapy
failure. Despite that, HFNC is frequently used, safe and effec-
tive  therapy for  children requiring  respiratory  support  in
PICU.
ETHICAL APPROVAL:
This study was exempted from full ethical approval because of
observational  nature  of  this  study  by  the  Ethical  Review
Committee of the Aga Khan University (Ref #2019-1036-2634).
PATIENTS' CONSENT:
Because of  the  observational  nature  of  the  study which
didn’t  involve  any  patients’  interaction/intervention,  the
need  for  consent  was  waived  by  the  Ethical  Review
Committee.
CONFLICT OF INTEREST:
The authors declared no conflict of interest.
AUTHORS' CONTRIBUTION:
BS, AA: Wrote protocol  along with QA and AH guidance,
collected data, and contributed in manuscript writing. 
QA, AH: Conceived the idea and contributed in manuscript
writing.
QA: Analysed data.
All approved final form of the manuscript.
REFERENCES
Namachivayam P, Shann F, Shekerdemian L, Taylor A, van1.
Sloten I, Delzoppo C, et al. Three decades of pediatric inten-
sive care: Who was admitted, what happened in intensive
care, and what happened afterward. Pediatr Crit Care Med
2010; 11(5):549-55. doi: 10.1097/PCC.0b013 e3181ce7427
Xu XP, Zhang XC, Hu SL, Xu JY, Xie JF, Liu SQ, et al. Non-inva-2.
sive ventilation in acute hypoxemic nonhypercapnic respira-
tory  failure:  A  systematic  review and meta-analysis.  Crit
Care  Med  2017;  45(7):e727-e33.  do.'i:  10.1097/CCM.
0000000000002361.
Clayton  JA,  McKee  B,  Slain  KN,  Rotta  AT,  Shein  SL.3.
Outcomes of children with bronchiolitis treated with high-
-flow nasal cannula or noninvasive positive pressure ventila-
tion.  Pediatr  Crit  Care  Med  2019;  20(2):128-35.  doi:
10.1097/PCC.0000000000001798.
Morris  JV,  Kapetanstrataki  M,  Parslow  RC,  Davis  PJ,4.
Ramnarayan  P.  Patterns  of  use  of  heated  humidified  high-
-flow nasal cannula therapy in PICUs in the United Kingdom
and  republic  of  ireland.  Pediatr  Crit  Care  Me  2019;
20(3):223-32. doi: 10.1097/PCC.0000000000001805.
Liew Z, Fenton AC, Harigopal S, Gopalakaje S, Brodlie M,5.
O'Brien  CJ.  Physiological  effects  of  high-flow  nasal  cannula
therapy in preterm infants. Arch Dis Child Fetal Neonatal Ed
2020;  105(1):87-93.  doi:  10.1136/archdischild-2018-
316773.  
Franklin  D,  Babl  FE,  Schlapbach  LJ,  Oakley  E,  Craig  S,6.
Neutze  J,  et  al.  A  randomised  trial  of  high-flow  oxygen
therapy in infants with bronchiolitis.  N Engl J  Med  2018;
378(12):1121-31. doi: 10.1056/NEJMoa1714855.
••••••••••
